|
End-of-day quote
Australian S.E.
24/09/2026
|
5-day change | 1st Jan Change | ||
| 0.0240 AUD | +4.35% |
|
+4.35% | -31.43% |
| 09-21 | Syntara Receives AU$4.7 Million R&D Tax Incentive Refund for Fiscal 2026; Shares Rise 9% | MT |
| 08-27 | Syntara Limited Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
Published on 04/30/2026 at 06:20 am BST - Modified on 05/04/2026 at 01:36 pm BST
Presenter Speech
Matthew Wright (Attendees)
Welcome to the Syntara Investor Webinar and Q&A following announcements through the week regarding FDA feedback on the proposed Phase IIb trial of amsulostat
[
Select your edition
All financial news and data tailored to specific country editions
